论文部分内容阅读
近年来胰腺癌的发病率逐渐升高,确诊时多已为中晚期,手术切除率低,化疗在胰腺癌治疗中发挥重要作用。吉西他滨在多项研究中被证实为胰腺癌化疗的一线用药,但使用吉西他滨化疗后的患者总生存率并未得到明显改善,考虑为胰腺癌细胞对吉西他滨的耐药性。胰腺癌细胞对吉西他滨的耐药主要考虑为RRM1、ERCC1等相关基因的表达,目前此类研究仍处在初级阶段,通过RRM1、ERCC1的表达预测吉西他滨的化疗效果有待更近一步的研究。现对胰腺癌RRM1、ERCC1的表达与吉西他滨化疗效果的研究进展进行综述。
In recent years, the incidence of pancreatic cancer gradually increased, mostly diagnosed in the late stage, surgical resection rate is low, chemotherapy plays an important role in the treatment of pancreatic cancer. Gemcitabine has been shown to be a first-line agent for pancreatic cancer chemotherapy in several studies, but the overall survival of patients treated with gemcitabine has not been significantly improved, considering the resistance of pancreatic cancer cells to gemcitabine. The main consideration of pancreatic cancer cell resistance to gemcitabine is the expression of RRM1, ERCC1 and other related genes. At present, such studies are still in the primary stage. The prediction of the effect of gemcitabine chemotherapy through the expression of RRM1 and ERCC1 needs further study. The progress of research on the expression of RRM1 and ERCC1 in pancreatic cancer and the effect of gemcitabine chemotherapy is reviewed.